Literature DB >> 27122121

Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.

Anand N Malaviya1,2, S B Gogia3,4.   

Abstract

This study was conducted in order to study (a) seropositive RA patients for their prior caregivers, diagnosis makers, drugs and doses taken and (b) the disease status at the first visit and the last visit, from the standpoint of whether they received optimum or suboptimum DMARD treatment. Prospectively entered data were extracted from a rheumatology-specific electronic health record for demography, diagnostic delay, prior caregivers, diagnosis makers, intake of DMARDs and glucocorticoids and disease activity state at first presentation and at the last visit using structured query language. Among 316 patients, prior caregivers were orthopaedicians (73.4 %), alternative systems of medicine practitioners (62 %), internists (38 %), rheumatologists (35.8 %), general practitioners (17 %) and others (12 %). The diagnosis of RA was made by rheumatologists (55.6 %), orthopaedicians (21 %), internists (12.6 %), physiotherapists (3.5 %), homeopaths (2.8 %), general practitioner (2.1 %), neurologists (1.4 %) and Ayurvedic physicians (0.7 %). The mean and the median diagnostic delay among 142 patients where information was available were 18 and 8.5 months, respectively (SD +23.2). Thirty-two percent of the patients had early disease, 48 % established disease and 20 % late disease at presentation. Sixty-six percent of the patients had taken DMARDs-methotrexate (56 %), hydroxychloroquine (46.2 %), leflunomide (18.7 %) and sulfasalazine (20.6 %)-and often in combinations. Different preparations, doses and schedules of glucocorticoids were taken orally or parentally by 51 %. Only one (0.3 %) patient had taken biological DMARDs prior to visiting this clinic. High or moderate disease activity was present in 84 % at the first clinic visit that fell to 14 % at the last clinic visit. The majority of patients with RA were treated by orthopaedicians and practitioners of alternative systems of medicine with only a third by rheumatologists. In 80 % of patients, the diagnosis was made 18 months at the onset, yet in 84 %, the disease control was poor. Non-use or suboptimal use of methotrexate appeared to be the main reason.

Entities:  

Keywords:  Care providers; Diagnosis delay; Drug treatment; India; Low-dose methotrexate; Rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 27122121     DOI: 10.1007/s10067-016-3283-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care.

Authors:  Daniel Aletaha; Josef S Smolen
Journal:  Best Pract Res Clin Rheumatol       Date:  2007-08       Impact factor: 4.098

2.  Methotrexate: the gold standard without standardisation.

Authors:  Jonathan Kay; Rene Westhovens
Journal:  Ann Rheum Dis       Date:  2009-07       Impact factor: 19.103

3.  The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.

Authors:  Glen S Hazlewood; J Carter Thorne; Janet E Pope; Daming Lin; Diane Tin; Gilles Boire; Boulos Haraoui; Carol A Hitchon; Edward C Keystone; Shahin Jamal; Vivian P Bykerk
Journal:  Ann Rheum Dis       Date:  2015-05-15       Impact factor: 19.103

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.

Authors:  Martin M Crane; Maneesh Juneja; Jeffery Allen; Regina H Kurrasch; Myron E Chu; Emilia Quattrocchi; Stephanie C Manson; David J Chang
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-12       Impact factor: 4.794

6.  Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population.

Authors:  Eswar Krishnan; Tuulikki Sokka; Arja Häkkinen; Helen Hubert; Pekka Hannonen
Journal:  Arthritis Rheum       Date:  2004-03

7.  The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1990-10

8.  Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register.

Authors:  C Austad; T K Kvien; I C Olsen; T Uhlig
Journal:  Ann Rheum Dis       Date:  2013-10-15       Impact factor: 19.103

Review 9.  Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.

Authors:  K Visser; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103

10.  Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study.

Authors:  Elisa Gremese; Fausto Salaffi; Silvia Laura Bosello; Alessandro Ciapetti; Francesca Bobbio-Pallavicini; Roberto Caporali; Gianfranco Ferraccioli
Journal:  Ann Rheum Dis       Date:  2012-07-13       Impact factor: 19.103

View more
  3 in total

1.  Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen.

Authors:  Anand Narayan Malaviya
Journal:  Clin Rheumatol       Date:  2016-09-06       Impact factor: 2.980

Review 2.  Rheumatology science and practice in India.

Authors:  Durga Prasanna Misra; Aman Sharma; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2018-07-19       Impact factor: 3.580

3.  Ultrasonography in Early Rheumatoid Arthritis of Hand and Wrist Joints: Comparison with Magnetic Resonance Imaging.

Authors:  Sundeep Malla; Surabhi Vyas; Ashu Seith Bhalla; Uma Kumar; Sandeep Kumar; Arun Kumar Gupta
Journal:  Indian J Orthop       Date:  2020-07-02       Impact factor: 1.251

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.